Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002950 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
A Phase 2 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01002950 is a Phase 2 study that has completed, run by Kubota Vision. The registered enrollment target is 72 participants.
The verdict
NCT01002950, a Phase 2 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
Interventions
- DRUG Matching placebo
- DRUG ACU-4429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002950
The ClinicalTrials.gov registry entry for NCT01002950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT01002950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002950 about?
NCT01002950 is a clinical study titled "Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
What is the current status of trial NCT01002950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-10. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01002950?
The interventions under investigation include: Matching placebo (DRUG), ACU-4429 (DRUG).
Who is sponsoring clinical trial NCT01002950?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.